Literature DB >> 3396946

Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

A J Greenstein1, P Lachman, D B Sachar, J Springhorn, T Heimann, H D Janowitz, A H Aufses.   

Abstract

The surgical indications in 770 patients with Crohn's disease undergoing intestinal resection at The Mount Sinai Hospital from 1960-83 have been reviewed. Surgical indications were divided into two principal categories: 375 cases with perforating indications and 395 cases non-perforating. Among 292 patients who underwent second operations for recurrent Crohn's disease, the indications for second operation were closely dependent on the indication for primary resection. Second operations were undertaken for perforating indications much more often among cases where the initial indication had been perforating, than among those whose initial indications had been non-perforating (73% v 29%, p less than 0.00001). This trend to similarities in the indications which bring patients to surgery was maintained within each anatomical category of Crohn's disease and even between second and third operations (p less than 0.001). Operations for perforating indications were followed by reoperation approximately twice as fast as operations for non-perforating indications, whether going from first to second operation (perforating 4.7 v non-perforating 8.8 years, p less than 0.001), or from second to third (perforating 2.3 v non-perforating 5.2 years, p less than 0.005). Crohn's disease thus seems to occur in two different clinical patterns, independent of anatomic distribution. These are a relatively aggressive perforating type and a more indolent non-perforating type, which tend to retain their identities between repeated operations and to influence the speed with which reoperation occurs.

Entities:  

Mesh:

Year:  1988        PMID: 3396946      PMCID: PMC1433651          DOI: 10.1136/gut.29.5.588

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  Indications for surgery in Crohn's disease: analysis of 500 cases.

Authors:  R G Farmer; W A Hawk; R B Turnbull
Journal:  Gastroenterology       Date:  1976-08       Impact factor: 22.682

2.  Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates.

Authors:  A J Greenstein; D B Sachar; B S Pasternack; H D Janowitz
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

3.  Proximal recurrence and the fate of the rectum following excisional surgery for Crohn's disease of the large bowel.

Authors:  M R Lock; V W Fazio; R G Farmer; D G Jagelman; I C Lavery; F L Weakley
Journal:  Ann Surg       Date:  1981-12       Impact factor: 12.969

4.  Prognosis after resection of chronic regional ileitis.

Authors:  J E Lennard-Jones; G A Stalder
Journal:  Gut       Date:  1967-08       Impact factor: 23.059

5.  Recurrence of Crohn's disease after primary excisional surgery.

Authors:  F T De Dombal; I Burton; J C Goligher
Journal:  Gut       Date:  1971-07       Impact factor: 23.059

6.  Risk factors for postoperative recurrence of Crohn's disease.

Authors:  D B Sachar; D M Wolfson; A J Greenstein; J Goldberg; R Styczynski; H D Janowitz
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

7.  Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication.

Authors:  G Whelan; R G Farmer; V W Fazio; M Goormastic
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

  7 in total
  81 in total

1.  The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn's disease.

Authors:  T Yamamoto; M R Keighley
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence.

Authors:  J P Achkar; B Shen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

3.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

4.  Intraoperative enteroscopy detects more lesions but is not predictive of postoperative recurrence in Crohn's disease.

Authors:  M Esaki; T Matsumoto; K Hizawa; K Aoyagi; R Mibu; M Iida; M Fujishima
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

Review 5.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

6.  Risk factors for surgery and postoperative recurrence in Crohn's disease.

Authors:  O Bernell; A Lapidus; G Hellers
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

7.  Current trends in inflammatory bowel disease: the natural history.

Authors:  Ebbe Langholz
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

8.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

9.  Molecular evidence for two forms of Crohn disease.

Authors:  E C Gilberts; A J Greenstein; P Katsel; N Harpaz; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Postoperative outcome of Crohn's disease in 30 children.

Authors:  M Besnard; O Jaby; J F Mougenot; L Ferkdadji; A Debrun; C Faure; P Delagausie; M Peuchmaur; Y Aigrain; J Navarro; J P Cézard
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.